Skip to main content

About your Search

Search Results 0 to 1 of about 2 (some duplicates have been removed)
immune to the fiscal cliff-induced recession. people do not stop taking life-saving medicines just because the economy slows down. alexia, on the other hand, not no. 23409 so hot. the stock has tripled since i first got behind it it's down about 14% since i highlighted it as an anointed growth stock two months ago. that's unacceptable. alexia is a orphan drug maker whose lead drug has been incredibly successful. however, even though alexia raised guidance, not unlike tractor supply, the stock sold off because the sales only met expectations rather than beating them. given the huge run in the stock going to the quarter. alexia had to do more than just meet the expectations. they had to beat that and crush them. and this time around, it got crushed. that said, to me the market overreacted, alexia has received fda approval to use solera for new indication that could be worth $900 million in peak sales and another $2.5 billion worth of new indications that the company is working on for this one medication. plus intriguing things in the pipe. although they're still in the early stages o
Search Results 0 to 1 of about 2 (some duplicates have been removed)